25. October, 2023
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children
The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number...
21. September, 2023
Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of...
12. September, 2023
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children
On 12 September – Cessatech A/S (“Cessatech” or “the Company”) announces that EMA’s Paediatric...
27. June, 2023
On 27 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...
15. March, 2022
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...
3. March, 2022
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
2. February, 2021
Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.Team
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.See details
Stay up to date!
Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.